为您找到相关结果约500个

你是不是要搜索 期刊Ciltacabtagene Autoleucel（Cilta-cel） 点击跳转

Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory

Safety and efficacy of standard of care ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory

of Neurologic Adverse Events in the CARTITUDE-2 Study of Patients with Multiple Myeloma Treated with CiltacabtageneAutoleucel (Cilta-Cel)

Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with CiltacabtageneAutoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Cranial Nerve Impairment in the CARTITUDE-1, CARTITUDE-2 Cohorts A, B, and C, and Cartitude-4 Studies of CiltacabtageneAutoleucel (Cilta-cel)

Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With CiltacabtageneAutoleucel (cilta-cel) in CARTITUDE-1

Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed

Comparison of ciltacabtagene autoleucel (cilta-cel) with the current standard of care in triple-exposed

CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMADIRECTED CAR-T

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Cilta-cel OK'd for Multiple Myeloma

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a

Ciltacabtagene autoleucel for the treatment of multiple myeloma

Trends of BCMA Re-emergence Post Ide-cel and Cilta-cel in Myeloma

Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study

为您找到相关结果约500个

共500条页码: 1/34页15条/页